GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Balaxi Pharmaceuticals Ltd (NSE:BALAXI) » Definitions » E10

Balaxi Pharmaceuticals (NSE:BALAXI) E10 : ₹3.62 (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Balaxi Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Balaxi Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was ₹0.970. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹3.62 for the trailing ten years ended in Dec. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2025-04-11), Balaxi Pharmaceuticals's current stock price is ₹66.75. Balaxi Pharmaceuticals's E10 for the quarter that ended in Dec. 2024 was ₹3.62. Balaxi Pharmaceuticals's Shiller PE Ratio of today is 18.44.

During the past 10 years, the highest Shiller PE Ratio of Balaxi Pharmaceuticals was 28.29. The lowest was 14.72. And the median was 19.99.


Balaxi Pharmaceuticals E10 Historical Data

The historical data trend for Balaxi Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Balaxi Pharmaceuticals E10 Chart

Balaxi Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Balaxi Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 3.52 3.62

Competitive Comparison of Balaxi Pharmaceuticals's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Balaxi Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Balaxi Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Balaxi Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Balaxi Pharmaceuticals's Shiller PE Ratio falls into.


;
;

Balaxi Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Balaxi Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.97/158.3229*158.3229
=0.970

Current CPI (Dec. 2024) = 158.3229.

Balaxi Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201503 0.002 97.163 0.003
201506 -0.020 99.841 -0.032
201509 -0.016 101.753 -0.025
201512 -0.024 102.901 -0.037
201603 0.400 102.518 0.618
201606 -0.034 105.961 -0.051
201609 -0.020 105.961 -0.030
201612 -0.024 105.196 -0.036
201703 -0.035 105.196 -0.053
201706 -0.044 107.109 -0.065
201709 -0.228 109.021 -0.331
201712 -0.094 109.404 -0.136
201803 -0.142 109.786 -0.205
201806 -0.086 111.317 -0.122
201809 0.144 115.142 0.198
201812 0.782 115.142 1.075
201903 0.452 118.202 0.605
201906 0.678 120.880 0.888
201909 0.228 123.175 0.293
201912 0.494 126.235 0.620
202003 0.292 124.705 0.371
202006 1.740 127.000 2.169
202009 2.024 130.118 2.463
202012 2.190 130.889 2.649
202103 1.674 131.771 2.011
202106 2.142 134.084 2.529
202109 2.410 135.847 2.809
202112 2.436 138.161 2.791
202203 2.542 138.822 2.899
202206 2.830 142.347 3.148
202209 3.098 144.661 3.391
202212 1.606 145.763 1.744
202303 1.570 146.865 1.692
202306 -8.100 150.280 -8.534
202309 2.810 151.492 2.937
202312 2.660 152.924 2.754
202403 2.146 153.035 2.220
202406 1.170 155.789 1.189
202409 0.840 157.882 0.842
202412 0.970 158.323 0.970

Add all the adjusted EPS together and divide 10 will get our e10.


Balaxi Pharmaceuticals  (NSE:BALAXI) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Balaxi Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=66.75/3.62
=18.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 10 years, the highest Shiller P/E Ratio of Balaxi Pharmaceuticals was 28.29. The lowest was 14.72. And the median was 19.99.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Balaxi Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Balaxi Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Balaxi Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Phase-III, Road No: 81, Jubilee Hills, Plot No.409, H,No: 8-2-293, MAPS Towers, 3rd Floor, Hyderabad, TG, IND, 500 096
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. Geographically it earns key revenue from Guatemala.

Balaxi Pharmaceuticals Headlines

No Headlines